SciSparc Ltd. (SPRC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd., a pharmaceutical firm focused on central nervous system disorders, has launched a clinical trial in Israel for SCI-210, a treatment aimed at alleviating symptoms of autism spectrum disorder (ASD). This innovative therapy combines cannabidiol (CBD) with SciSparc’s unique formulation, CannAmide™, and is being tested on children aged five to 18. The company plans to enroll 60 participants for the trial and aims for commercialization in Israel and subsequently other markets upon regulatory approval.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.